Published Date: 13 Mar 2023
The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.
Read Full NewsBreast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the main causes of cancer-related mortality. Precisely predicting whether ...
The periodization of exercise training could give people undergoing cancer treatment and those in recovery a tailored pathway to support strength and resilience during the challenging journey of cancer care and rehabilitation.
A new clinical trial led by University of Alberta researchers is exploring whether heavy strength training is a safe and beneficial way to help combat the long-term physical challenges faced by head and neck cancer survivors.
1.
November 2023, Medical Bulletin 04/.
2.
Common intracellular toxin could help fight leukemia
3.
Early breast cancer detection may be possible with a wearable ultrasound scanner.
4.
A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.
5.
Study identifies new approach to protect the brain during radiation therapy
1.
How to Manage Dic with the Right Treatment Approach
2.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
3.
Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment
4.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
5.
Does Lactate Signal Anemia? Exploring the Complexities of Hyperlactatemia and Red Blood Cell Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
5.
Navigating the Complexities of Ph Negative ALL - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation